“We invested in Serigen because of the stellar promoters and the groundbreaking products they’ve brought to market. We’re very happy with how production is going, how people are adopting the products, and how Serioss is being used in clinical trials across many hospitals. We really hope this product is going to change how wound care is done in the country.”

“Serigen fulfilled all the desires or needs in my heart to actually invest in a company… I thought the product which Serigen was wanting to develop made fundamental sense. Silk as an inert substance would be very valuable when inserted into bone grafts and also in non-healing ulcers. I’m also very fortunate to have met a good group of likeminded individuals who run the company… their hearts and minds are in the right place about wanting to make a difference.”

“What sets Serigen apart is not just their innovation, but their resilience. In a domain where product development cycles are long and regulatory hurdles high, they have shown remarkable commitment and resourcefulness, navigating complexities without compromising on quality or ethics. I believe Serigen Mediproducts is poised to make a significant impact in the medtech landscape, and I offer my full support and confidence in their future success”

“We believe Serigen’s revolutionary silk-based platform is both versatile and compelling. With a global market opportunity of nearly $7B and a distinct Indian cost advantage, Serigen is uniquely positioned to scale. Backed by an exceptional team with deep market insight, the company represents a quintessential blend of IP-driven innovation, impact, and executional strength. ”